NEUVOGEN, a United States-based immunoncology company, has named Christian Ottensmeier MD, PhD, FRCP as the head of its Scientific Advisory Board, it was reported on Monday.
Dr Ottensmeier is serving as a professor of Immuno-Oncology, University of Liverpool School of Medicine, Institute of Systems, Molecular and Integrative Biology, The Clatterbridge Cancer Center NHS Foundation Trust. Presently, he also serves as adjunct professor at La Jolla Institute for Immunology.
Other members of the company's Scientific Advisory Board are David Reardon, MD, Dr Abul Abbas, MBBS and Hideho Okada, MD, PhD.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories